FI113183B - Menetelmä fuusioproteiinien valmistamiseksi - Google Patents

Menetelmä fuusioproteiinien valmistamiseksi Download PDF

Info

Publication number
FI113183B
FI113183B FI920923A FI920923A FI113183B FI 113183 B FI113183 B FI 113183B FI 920923 A FI920923 A FI 920923A FI 920923 A FI920923 A FI 920923A FI 113183 B FI113183 B FI 113183B
Authority
FI
Finland
Prior art keywords
plasmid
oligonucleotide
gene
sequence
protein
Prior art date
Application number
FI920923A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI920923A0 (fi
Inventor
Paul Habermann
Eugen Uhlmann
Brian Seed
Wolfgang Ulmer
Siegfried Stengelin
Original Assignee
Gen Hospital Corp
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Aventis Pharma Gmbh filed Critical Gen Hospital Corp
Publication of FI920923A0 publication Critical patent/FI920923A0/fi
Application granted granted Critical
Publication of FI113183B publication Critical patent/FI113183B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI920923A 1989-08-29 1992-02-28 Menetelmä fuusioproteiinien valmistamiseksi FI113183B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39987489A 1989-08-29 1989-08-29
US39987489 1989-08-29
PCT/US1990/004840 WO1991003550A1 (en) 1989-08-29 1990-08-28 Fusion proteins, their preparation and use
US9004840 1990-08-28

Publications (2)

Publication Number Publication Date
FI920923A0 FI920923A0 (fi) 1992-02-28
FI113183B true FI113183B (fi) 2004-03-15

Family

ID=23581315

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920923A FI113183B (fi) 1989-08-29 1992-02-28 Menetelmä fuusioproteiinien valmistamiseksi

Country Status (20)

Country Link
EP (1) EP0489780B1 (de)
JP (1) JP3043803B2 (de)
KR (1) KR0159786B1 (de)
AT (1) ATE173018T1 (de)
AU (1) AU638277B2 (de)
CA (1) CA2065146C (de)
CY (1) CY2168B1 (de)
DE (1) DE69032743T2 (de)
DK (1) DK0489780T3 (de)
ES (1) ES2124216T3 (de)
FI (1) FI113183B (de)
GR (1) GR1005153B (de)
HK (1) HK1012026A1 (de)
HU (1) HU216069B (de)
IE (1) IE903120A1 (de)
IL (1) IL95495A (de)
NO (1) NO308667B1 (de)
PT (1) PT95111B (de)
WO (1) WO1991003550A1 (de)
ZA (1) ZA906839B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426036A (en) * 1987-05-05 1995-06-20 Hoechst Aktiengesellschaft Processes for the preparation of foreign proteins in streptomycetes
DK0600372T3 (da) 1992-12-02 1997-08-11 Hoechst Ag Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer.
DE59409816D1 (de) * 1993-04-27 2001-09-13 Hoechst Ag Amorphe monosphärische Formen von Insulinderivaten
WO1995009914A1 (fr) * 1993-10-05 1995-04-13 Asahi Glass Company Ltd. Vecteur de multiclonage, vecteur d'expression, et production d'une proteine exogene au moyen dudit vecteur d'expression
US6001604A (en) * 1993-12-29 1999-12-14 Bio-Technology General Corp. Refolding of proinsulins without addition of reducing agents
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
US5683987A (en) * 1994-07-12 1997-11-04 The Board Of Regents Of The University Of Nebraska Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
DE59711533D1 (de) 1996-07-26 2004-05-27 Aventis Pharma Gmbh Insulinderivate mit erhöhter Zinkbindung
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE19915938A1 (de) 1999-04-09 2000-10-19 Aventis Pharma Gmbh Herstellung von pankreatischer Procarboxypeptidase B, Isoformen und Muteinen davon und ihre Verwendung
DE19930676B4 (de) 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
AU2003280870A1 (en) * 2002-11-12 2004-06-03 Ckd Bio Corp. Plasmids expressing human insulin and the preparation method for human insuling thereby
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
AU2009203810B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
AU2009203809B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
UY33025A (es) 2009-11-13 2011-06-30 Sanofi Aventis Deustschland Gmbh Composicion farmaceutica que comprende un agonista de glp-1 metionina
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
DK2739646T3 (en) 2011-05-10 2018-02-26 Stefan Hermann COMPREHENSIVE BUFFER SYSTEM FOR RENATURING HUMAN PROINSULIN OR PROINSULIN DERIVATIVES
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP5858945B2 (ja) 2012-03-15 2016-02-10 アークレイ株式会社 酵素を用いた測定方法
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP3927825A4 (de) * 2019-02-19 2023-05-31 The Trustees of Princeton University System und verfahren zur lichtregulierten oligomerisierung und phasentrennung von gefalteten domänen und von mit rna-granulation assoziierten proteindomänen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4431739A (en) * 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
JPS61264000A (ja) * 1985-03-21 1986-11-21 イミユネツクス　コ−ポレイシヨン 標識ペプチドによるタンパク質の合成
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
JPH05501799A (ja) 1993-04-08
DE69032743D1 (de) 1998-12-10
HU9200674D0 (en) 1992-08-28
AU638277B2 (en) 1993-06-24
GR1005153B (el) 2006-03-13
GR900100635A (el) 1991-12-30
ZA906839B (en) 1991-06-26
DK0489780T3 (da) 1999-07-19
ES2124216T3 (es) 1999-02-01
IE903120A1 (en) 1991-03-13
HU216069B (hu) 1999-04-28
CY2168B1 (en) 2002-08-23
DE69032743T2 (de) 1999-06-17
EP0489780B1 (de) 1998-11-04
JP3043803B2 (ja) 2000-05-22
IL95495A (en) 1996-10-16
HK1012026A1 (en) 1999-07-23
EP0489780A4 (en) 1992-08-12
NO920774L (no) 1992-04-28
HUT60327A (en) 1992-08-28
PT95111A (pt) 1991-05-22
CA2065146A1 (en) 1991-03-01
WO1991003550A1 (en) 1991-03-21
NO920774D0 (no) 1992-02-27
ATE173018T1 (de) 1998-11-15
KR0159786B1 (ko) 1998-11-16
EP0489780A1 (de) 1992-06-17
FI920923A0 (fi) 1992-02-28
CA2065146C (en) 2002-07-23
AU6287290A (en) 1991-04-08
PT95111B (pt) 1998-10-30
NO308667B1 (no) 2000-10-09
IL95495A0 (en) 1991-06-30

Similar Documents

Publication Publication Date Title
FI113183B (fi) Menetelmä fuusioproteiinien valmistamiseksi
US5358857A (en) Method of preparing fusion proteins
US5227293A (en) Fusion proteins, their preparation and use
AU615760B2 (en) Insulin analogues
FI102182B (fi) Menetelmä ihmisen insuliinianalogien valmistamiseksi
CA1340823C (en) Insulin precursors, process for their preparation and process for the preparation of human insulin
CA1340371C (en) Methods and products for facile microbial expression of dna sequences
SK278576B6 (en) Expression vectors for increased production polypeptides, plasmides containing these vectors, host cells containing these plasmides, gained products, connecting methods and use
CA2006578A1 (en) Human insulin analogues
JP4624495B2 (ja) ヒト・インスリンの生成
JPH0759193B2 (ja) 外来性蛋白質発現用クロ−ニングベクタ−
US4828988A (en) Hybrid polypeptides comprising somatocrinine and alpha1 -antitrypsin, method for their production from bacterial clones and use thereof for the production of somatocrinine
CA1338900C (en) Escherichia coli plasmid vector with lipoprotein promoter and modified shine-dalgarno sequence
Mayne et al. Direct expression of human growth in Escherichia coli with the lipoprotein promoter
US6054291A (en) Expression vectors for enhanced production of polypeptides, plasmids containing the vectors, hosts containing the plasmids, products manufactured thereby and related methods
KR100381494B1 (ko) 인간인슐린의제조방법
JPH08140679A (ja) 微生物によるラットβ２−マイクログロブリン生産